AKRO (Akero Corp) Earnings growth in current year

AKRO (Akero Corp) - company brandmark

Akero Therapeutics (AKRO) is developing a therapy to combat MASH, targeting a multi-billion dollar segment of obesity treatment. The annual variable EPS demonstrates how the 3.70 metric reflects current dynamics, while breakthrough methods for treating cirrhosis are undergoing clinical trials. The business's financial success is based on the commercialization of innovations and their subsequent insurance reimbursement.

AKRO: Akero Therapeutics Earnings per share growth in current year 07/04/2022 - 12/20/2025

Financial and market metric breakdowns for Akero Therapeutics, Inc. (AKRO)

- share price and expert price forecast:
Basic company analysis:AKRO - Akero Corp
Finished products of Akero

Akero Therapeutics' focus on the organic development of its NASH drug without an M&A strategy makes net income dynamics a key indicator of R&D investment efficiency. This relative change in EPS compared to the same period last year measures the annual growth rate of earnings per share, allowing investors to assess the sustainability of returns against inflationary pressure and identify the risks of acquiring the asset at historical peaks.

Main competitors

ASND: Net earnings per one share growth for the current year|MDGL (Madrigal Corp) - Earnings growth in current year|Earnings growth in current year Corcept Therapeutics|Earnings growth in current year RYTM|Earnings per share growth in current year MTSR (Metsera, Inc.)|Earnings per share growth in current year moonlaketx.com MLTX|Crinetics Corp (CRNX) - Earnings per share growth rate in current year|NAMS - Earnings per share growth in current year|SLNO: Earnings per share growth in current year|FOLD: Earnings growth in current year|ETNB - Expected net earnings per share growth this year|Earnings per share growth in current year Agios Corp|Structure Corp (GPCR) - Expected net earnings per share growth this year|Earnings per share growth in current year mimedx.com (MDXG)|Net earnings per share growth this year rezolutebio.com RZLT|Earnings per share growth in current year Lexicon Pharmaceuticals, Inc. LXRX|MBX Bio - Earnings per share growth in current year|ALT: Net earnings per share growth this year|AARD - Earnings growth in current year|SGMT: Earnings growth in current year|Earnings per share growth rate in current year BioAge Labs, Inc. (BIOA)|Earnings per share growth in current year Biomea Fusion Inc|Earnings per share growth this year QNCX (Quince Therapeutics)|Net earnings per share growth this year GUTS (Fractyl Health)|Net earnings per one share growth for the current year VTVT|Agape ATP Corporation - Net earnings per share growth this year|Earnings per share increase in current year PLUR|Synlogic Inc. - Earnings growth in current year|LPCN (Lipocine) - Earnings per share growth this year|MTNB (Matinas BioPharma Holdings Inc.) - Net earnings per share growth this year|SPRB (Spruce Biosciences, Inc.) - Earnings per share growth in current year|GLTO (galecto.com) - Earnings growth in current year|Net earnings per share growth this year carmellrx.com (CTCX)|Earnings per share growth in current year Lumos Pharma (LUMO)|ONVO (Organovo Holdings) - Earnings per share increase in current year|radiuspharm.com - Net earnings per share growth this year